## Considering the methodological limitations in the evidence base of antidepressants for depression: A reanalysis of a network meta-analysis

Klaus Munkholm <sup>a</sup>, Asger Sand Paludan-Müller <sup>a</sup>, Kim Boesen <sup>a</sup>

<sup>a</sup> Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark

S1 Table

**S1 Table.** Comparison between the outcomes of total dropout rates and dropouts due to adverse events as reported by Cipriani et al.<sup>1</sup> and the data reported in the clinical study reports.

Trial ID (From Cipriani et al. dataset)	Total dropouts reported by Cipriani et al. compared with clinical study reports*	Dropouts due to adverse events reported by Cipriani et al. compared with clinical study reports**
Goldstein2002 (HMAQ - Study Group A)	Match	Match
Study F1J-MC-HMAQ - Study Group B (starting page in the pdf document: 147)	Match	Not reported
Goldstein2004a (HMAT - Study Group A, ID#4091)	Discrepancy	Match
Goldstein2004b (HMAT - Study Group B, ID#4091)	Match	Discrepancy
Detke2004 (HMAY Study Group A)	Match	Match
Perahia2006 (HMAY - Study Group B)	Match	Match
Detke2002a (HMBH - Study Group A)	Match	Match
Detke2002b (HMBH - Study Group B)	Match	Discrepancy
0600B-367	Not reported	Not reported
0600B1-384	Discrepancy	Discrepancy
VEN 600A-303 (FDA)	Discrepancy	Match
Cunningham1994 (VEN 600A-302 FDA)	Discrepancy	Match
VEN 600A-313 (FDA)	Discrepancy	Match
0600A1-372	Not reported	Not reported
Thase1997 (VEN XR 209 FDA)	Match	Match
Rudolph1998 (VEN 600A-203 (FDA)	Match	Match
SER 101 (FDA)	Match	Not reported
Fabre1995 (SER 103 FDA)	Match	Match
SER 310 (FDA)	Discrepancy	Not reported

\*Our comparison considered all treatment arms in the trials. If data for all arms matched, we assigned an assessment of 'match'; if data for any arm differed but were reported, we assigned an assessment of 'discrepancy'; if data for any arm was not reported, we assigned an assessment of 'not reported'.

## References

1. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* 2018 doi: 10.1016/S0140-6736(17)32802-7 [published Online First: 2018/02/27]